Smith & Nephew (LON:SN) was downgraded by stock analysts at BNP Paribas to a “neutral” rating in a research note issued to investors on Friday. They presently have a GBX 1,525 ($19.93) target price on the stock, up from their previous target price of GBX 1,475 ($19.27). BNP Paribas’ price objective suggests a potential upside of 0.66% from the stock’s current price.
Other analysts have also recently issued reports about the stock. Berenberg Bank raised their price target on shares of Smith & Nephew from GBX 1,370 ($17.90) to GBX 1,475 ($19.27) and gave the stock a “hold” rating in a report on Friday, November 2nd. HSBC cut shares of Smith & Nephew to a “hold” rating and raised their price target for the stock from GBX 1,400 ($18.29) to GBX 1,500 ($19.60) in a report on Tuesday, October 16th. Credit Suisse Group raised their price target on shares of Smith & Nephew from GBX 1,330 ($17.38) to GBX 1,390 ($18.16) and gave the stock a “neutral” rating in a report on Friday. Deutsche Bank restated a “hold” rating on shares of Smith & Nephew in a report on Friday. Finally, UBS Group restated a “neutral” rating on shares of Smith & Nephew in a report on Friday, October 26th. Eight equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of GBX 1,479.40 ($19.33).
SN stock opened at GBX 1,515 ($19.80) on Friday. Smith & Nephew has a 52 week low of GBX 1,173 ($15.33) and a 52 week high of GBX 1,442 ($18.84).
Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.
Recommended Story: Quiet Period
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.